RESUMEN
BACKGROUND: Surgery is the third most common cause of mortality worldwide. Focused cardiac ultrasound (FOCUS) yields information on cardiac status and discloses the presence of unknown pathology. Preoperative FOCUS changes patient treatment, allowing for a patient-tailored anaesthesia. We hypothesised that preoperative FOCUS would reduce the proportion of patients who were either admitted to hospital for more than 10 days or who were dead within 30 days after high-risk, non-cardiac surgery. METHODS: This was a randomised, controlled, multi-center study. Patients ≥65 years of age, admitted for urgent orthopaedic- or abdominal surgery, scheduled for general- or neuraxial anaesthesia and with ASA 3/4 were eligible for inclusion. Patients were randomised in a 1:1 ratio to preoperative FOCUS or no preoperative FOCUS performed in accordance with a predefined protocol. Primary endpoint was the proportion of patients admitted more than 10 days or who were dead within 30 days. Secondary endpoints included major complications, days of admission and changes in anaesthesia handling. RESULTS: During the second COVID-19 wave the study monitoring committee terminated the study prematurely. We included 338 patients of which 327 were included in the final analysis. In the FOCUS group, 41/163 (25%) patients met the criteria for the primary endpoint versus 35/164 (21%) for the control group, adjusted odds ratio 1.37 (95% CI 0.86-2.30), p = .36. The proportions of patients who developed major complications did not differ significantly between groups. Length of hospital stay was 4 (3-8) days in the FOCUS group and 4 (3-7) days on the control group (adjusted p = .24). CONCLUSION: The routine availability of preoperative FOCUS assessment in this cohort does not appear to reduce the risk for hospitalisation exceeding 10 days or 30-day mortality, although study enrolment was prematurely terminated.
Asunto(s)
COVID-19 , Humanos , Tiempo de Internación , Hospitalización , Corazón , UltrasonografíaRESUMEN
INTRODUCTION: Perioperative mortality and morbidity remain substantial in acute surgery. Risk factors include known cardiovascular disease, but preoperative screening is insensitive to occult cardiopulmonary conditions. Focused cardiac ultrasound (FOCUS) can disclose both structural and functional cardiac disease and provides insight into the patient's haemodynamic status. This study aims to clarify whether preoperative FOCUS changes clinical outcomes in high-risk patients. METHODS: This is a multi-centre, randomised, controlled, prospective study including patients ≥ 65 years of age scheduled for acute/emergency abdominal- or orthopaedic surgery. A total of 800 patients will be randomised to ± application of preoperative FOCUS. The primary endpoint is the proportion of patients admitted to hospital > 10 days or death within 30 days of surgery. The secondary endpoints include changes in the anaesthesia approach facilitated by FOCUS, biomarkers of organ function and perioperative complications. CONCLUSIONS: The knowledge generated from this study may facilitate changes in the anaesthesia evaluation and decision process and, consequently, in the entire perioperative anaesthesia clinical practice. The study has the potential to reduce the risk of perioperative cardiopulmonary complications which directly implies improved patient outcome and reduced hospital costs. FUNDING: The Research Fund of the Department of Anaesthesiology, Randers Regional Hospital, The Central Denmark Region's Medical Research Fund and the Hospital of Southern Jutland. TRIAL REGISTRATION: NCT03501927.
Asunto(s)
Enfermedades Cardiovasculares/diagnóstico por imagen , Sistemas de Atención de Punto , Complicaciones Posoperatorias/prevención & control , Cuidados Preoperatorios/métodos , Ultrasonografía/métodos , Abdomen/cirugía , Anciano , Anciano de 80 o más Años , Enfermedades Cardiovasculares/complicaciones , Femenino , Corazón/diagnóstico por imagen , Humanos , Masculino , Procedimientos Ortopédicos/efectos adversos , Complicaciones Posoperatorias/etiología , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de RiesgoRESUMEN
DNP is a weight-reducing agent, which has been revived through sale over the Internet. DNP uncouples the oxidative phosphorylation in cells, leading to an excessive production of heat. A 39-year-old male ingested four grams of DNP and developed severe muscular stiffness and eventually cardiac arrest. Intubation was unsuccessful, and tracheotomy was performed on scene. Ventilation proved impossible, and the patient was declared dead in the pre-hospital setting. Doctors need to recognize potential lethal intoxications. Symptomatic treatment is warranted.
Asunto(s)
2,4-Dinitrofenol/envenenamiento , Fármacos Antiobesidad/envenenamiento , 2,4-Dinitrofenol/química , Adulto , Fármacos Antiobesidad/química , Resultado Fatal , Humanos , Masculino , SuicidioRESUMEN
A 66 year-old woman developed severe hypotension and bronchospasm as a result of disulfiram-ethanol reaction (DER). She presented with sudden onset of severe life-threatening symptoms. The clinical signs of DER were treated successfully and symptomatically with intravenous fluids, catecholamines, inhalations and benzodiazepines in the intensive care unit. Fomepizole, an alcohol dehydrogenase inhibitor, was advocated as a specific treatment for DER. This case highlights the potential danger of DER.